Macrophage-derived reactive oxygen species protects against autoimmune priming with a defined polymeric adjuvant
2016 (English)In: Immunology, ISSN 0019-2805, E-ISSN 1365-2567, Vol. 147, no 1, p. 125-132Article in journal (Refereed) Published
Abstract [en]
Understanding the nature of adjuvants and the immune priming events in autoimmune diseases, such as rheumatoid arthritis, is a key challenge to identify their aetiology. Adjuvants are, however, complex structures with inflammatory and immune priming properties. Synthetic polymers provide a possibility to separate these functions and allow studies of the priming mechanisms in vivo. A well-balanced polymer, poly-N-isopropyl acrylamide (PNiPAAm) mixed with collagen type II (CII) induced relatively stronger autoimmunity and arthritis compared with more hydrophilic (polyacrylamide) or hydrophobic (poly-N-isopropylacrylamide-co-poly-N-tertbutylacrylamide and poly-N-tertbutylacrylamide) polymers. Clearly, all the synthesized polymers except the more hydrophobic poly-N-tertbutylacrylamide induced arthritis, especially in Ncf1-deficient mice, which are deficient in reactive oxygen species (ROS) production. We identified macrophages as the major infiltrating cells present at PNiPAAm-CII injection sites and demonstrate that ROS produced by the macrophages attenuated the immune response and the development of arthritis. Our results reveal that thermo-responsive polymers with high immune priming capacity could trigger an autoimmune response to CII and the subsequent arthritis development, in particular in the absence of NOX2 derived ROS. Importantly, ROS from macrophages protected against the autoimmune priming, demonstrating a critical regulatory role of macrophages in immune priming events.
Place, publisher, year, edition, pages
2016. Vol. 147, no 1, p. 125-132
Keywords [en]
adjuvant, arthritis, collagen type II, macrophages, poly-N-isopropylacrylamide
National Category
Clinical Medicine Biomaterials Science
Identifiers
URN: urn:nbn:se:hh:diva-48403DOI: 10.1111/imm.12546PubMedID: 26455429OAI: oai:DiVA.org:hh-48403DiVA, id: diva2:1703140
2022-10-122022-10-122025-10-01Bibliographically approved